ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.58
-0.02%
US Tech 100
20,355.20
0.45%
S&P 500
6,021.63
0.57%
US Dollar vs CAD
1.40638
0.07%
Bitcoin
92,684.25
0.77%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) News

ACRV

Acrivon Therapeutics (ACRV)

Acrivon Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACRV
DateTimeSourceHeadlineSymbolCompany
11/25/20243:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
11/18/20243:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
11/18/20243:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
11/18/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
11/18/20243:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
11/18/20243:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
11/18/20243:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
11/13/20246:06AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRVAcrivon Therapeutics Inc
11/13/20246:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
11/13/20246:00AMGlobeNewswire Inc.Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
10/21/20243:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
10/17/20247:00AMGlobeNewswire Inc.Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR SymposiumNASDAQ:ACRVAcrivon Therapeutics Inc
10/16/20243:00PMGlobeNewswire Inc.Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACRVAcrivon Therapeutics Inc
10/11/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
10/11/20247:00AMGlobeNewswire Inc.Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent ActivityNASDAQ:ACRVAcrivon Therapeutics Inc
10/03/20245:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
09/16/20245:43AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
09/14/20242:10AMGlobeNewswire Inc.Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysisNASDAQ:ACRVAcrivon Therapeutics Inc
09/10/20247:00AMGlobeNewswire Inc.Acrivon Therapeutics to Present at the Cantor Global Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
09/09/20246:00AMGlobeNewswire Inc.Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
08/23/20243:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
08/16/20243:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
08/16/20243:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
08/16/20243:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
08/16/20243:51PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
08/16/20243:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
08/16/20243:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
08/16/20243:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
08/13/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
08/13/20247:00AMGlobeNewswire Inc.Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACRV

Your Recent History

NASDAQ
SAVA
Cassava Sciences
USOTC
CBDW
1606 (PK)
USOTC
ENZC
Enzolytics (PK)
USOTC
MONI
Moon Equity (PK)
NASDAQ
ENTA
Enanta Pharmaceuticals
NASDAQ
AVXL
Anavex Life Sciences
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
GDVM
Global Developments (PK)
USOTC
ERHE
ERHC Energy (CE)
NYSE
AMC
AMC Entertainment
USOTC
HIRU
Hiru (PK)
USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
NASDAQ
LWLG
Lightwave Logic
NASDAQ
NB
NioCorp Developments
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Canada: TSX and TSXV Level 1

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1305.00 only $522.00